1-3 of 3
Claude H. T. Chan
Close
Sort by
Journal Articles

Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity

Andrew T. Vaughan, Chisako Iriyama, Stephen A. Beers, Claude H. T. Chan, Sean H. Lim, Emily L. Williams, Vallari Shah, Ali Roghanian, Bjorn Frendéus, Martin J. Glennie, Mark S. Cragg
Journal: Blood
Blood (2014) 123 (5): 669–677.
https://doi.org/10.1182/blood-2013-04-490821
Published: 2014
Includes: Supplemental data
Journal Articles

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

Waleed Alduaij, Andrei Ivanov, Jamie Honeychurch, Eleanor J. Cheadle, Sandeep Potluri, Sean H. Lim, Kazuyuki Shimada, Claude H. T. Chan, Alison Tutt, Stephen A. Beers, Martin J. Glennie, Mark S. Cragg, Tim M. Illidge
Journal: Blood
Blood (2011) 117 (17): 4519–4529.
https://doi.org/10.1182/blood-2010-07-296913
Published: 2011
Includes: Multimedia, Supplemental data
Journal Articles

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

Stephen A. Beers, Claude H. T. Chan, Sonya James, Ruth R. French, Kathrine E. Attfield, Claire M. Brennan, Anupama Ahuja, Mark J. Shlomchik, Mark S. Cragg, Martin J. Glennie
Journal: Blood
Blood (2008) 112 (10): 4170–4177.
https://doi.org/10.1182/blood-2008-04-149161
Published: 2008
Includes: Supplemental data